207 - Neglected Herpesviruses

Saturday, October 22, 2022

10:30 AM – 11:45 AM US ET

Location: 151 AB

Watch the live stream on the conference website.

All relevant financial disclosures have been mitigated.

Moderator(s)

Christine Johnston, MD, MPH

Associate Professor
Medicine
University of Washington
Seattle, Washington, United States

Disclosure(s): Abbvie: Advisor/Consultant (Terminated); Gilead Biosciences: Advisor/Consultant (Ongoing), Grant/Research Support (Ongoing); GSK: Advisor/Consultant (Ongoing); UpToDate Wolters Kluwer Health: Royalties (Ongoing)
Andrew Karaba, MD, PHD

Assistant Professor
Johns Hopkins
Baltimore, MD, United States

Disclosure(s): Roche Diagnostics: Advisor/Consultant (Ongoing)

Faculty(s)

Joshua Hill, MD

Assistant Professor
Fred Hutchinson Cancer Center; University of Washington
Seattle, Washington, United States

Disclosure(s): Allovir: Advisor/Consultant (), Grant/Research Support (); Covance/CSL: Advisor/Consultant (); CRISPR: Advisor/Consultant (); Deverra: Grant/Research Support (); Gilead: Grant/Research Support (); Karius: Advisor/Consultant (), Grant/Research Support (); Merck: Grant/Research Support (); Octapharma: Advisor/Consultant (); OptumHealth: Advisor/Consultant (); Oxford Immunotec: Grant/Research Support (); Pfizer: Advisor/Consultant (); Symbio: Advisor/Consultant (); Takeda: Advisor/Consultant ()

Slides
Maria Nagel, Medical Degree

Professor, Neurology and Ophthalmology
University of Colorado School of Medicine
Aurora, CO, United States

Disclosure(s): Merck and Company, Inc.: Expert Testimony (Ongoing)

Slides
Ramya Ramaswami, MD, MPH

Physician-Scientist Early Investigator
Center for Cancer Research, National Cancer Institute, National Institutes of Health

Disclosure(s): BMS/ Celgene: Grant/Research Support (Ongoing), Study drug and research support through collaborative agreement with NCI (Ongoing); CTI Biopharma: Study drug and research support through collaborative agreement with NCI (Ongoing); Eli Lilly: Study drug supply through collaboration with CTEP (Ongoing); EMD Serono: CRADA research agreement with NCI institution (Ongoing); Janssen: Study drug and research support through collaborative agreement with NCI (Ongoing); Merck & Co., Inc.: Study drug and research support through collaborative agreement with CTEP (Ongoing)

Slides

Disclosure(s):

Christine Johnston, MD, MPH: Abbvie: Advisor/Consultant (Terminated); Gilead Biosciences: Advisor/Consultant (Ongoing), Grant/Research Support (Ongoing); GSK: Advisor/Consultant (Ongoing); UpToDate Wolters Kluwer Health: Royalties (Ongoing)

Andrew Hoover Karaba, MD, PHD: Roche Diagnostics: Advisor/Consultant (Ongoing)

Joshua A. Hill, MD: Allovir: Advisor/Consultant (), Grant/Research Support (); Covance/CSL: Advisor/Consultant (); CRISPR: Advisor/Consultant (); Deverra: Grant/Research Support (); Gilead: Grant/Research Support (); Karius: Advisor/Consultant (), Grant/Research Support (); Merck: Grant/Research Support (); Octapharma: Advisor/Consultant (); OptumHealth: Advisor/Consultant (); Oxford Immunotec: Grant/Research Support (); Pfizer: Advisor/Consultant (); Symbio: Advisor/Consultant (); Takeda: Advisor/Consultant ()

Maria A. Nagel, Medical Degree: Merck and Company, Inc.: Expert Testimony (Ongoing)

Ramya Ramaswami, MD, MPH: BMS/ Celgene: Grant/Research Support (Ongoing), Study drug and research support through collaborative agreement with NCI (Ongoing); CTI Biopharma: Study drug and research support through collaborative agreement with NCI (Ongoing); Eli Lilly: Study drug supply through collaboration with CTEP (Ongoing); EMD Serono: CRADA research agreement with NCI institution (Ongoing); Janssen: Study drug and research support through collaborative agreement with NCI (Ongoing); Merck & Co., Inc.: Study drug and research support through collaborative agreement with CTEP (Ongoing)

CME Credits: Maximum of 1.25 hours of AMA PRA Category 1 Credit™
MOC Credits: Maximum of 1.25 hours of MOC Credit
CNE Credits: Maximum of 1.25 hours of ANCC Credit
ACPE Credits: ACPE 1.25 contact hours of pharmacy CE
ACPE Number: JA0007082-0000-22-002-L01-P

Learning Objectives:

At the conclusion of this session, participants will be able to:

explain how to interpret HHV-6 test results and treat HHV-6 in clinical practice;
describe new concepts in neurological syndromes related to HSV and VZV infection;
identify manifestations of HHV-8 infection and describe management strategies

Presentations:

10:30 AM – 10:55 AM US ET

HHV-6 in Your Differential Diagnosis: When to Consider and What to Do
Speaker: Joshua A. Hill, MD – Fred Hutchinson Cancer Center; University of Washington
10:55 AM – 11:20 AM US ET

Neurological Complications of VZV and HSV
Speaker: Maria A. Nagel, Medical Degree – University of Colorado School of Medicine
11:20 AM – 11:45 AM US ET

Splitting Instead of Lumping: An Update on HHV-8 Disease Manifestations and Their Treatments
Speaker: Ramya Ramaswami, MD, MPH – Center for Cancer Research, National Cancer Institute, National Institutes of Health